The Application of a Three-Step Proteome Analysis for Identification of New Biomarkers of Pancreatic Cancer
Table 3
(a) Serum tumor marker levels in patients with pancreatic cancer.
Gender
Age (years)
UICC-stage
Tumor size (mm)
CA19-9 (U/mL)
CEA (ng/mL)
ApoA-IV (AU)
GC (AU)
RBP4 (AU)
M
38
IA
10
26.2
2.3
262.1
35.9
54.2
M
50
IB
30
46.5
2.3
8.5
34.3
43.9
M
63
IIA
18
157
1.1
10.2
26.7
37.0
M*
62
IIA
38
9
5
70.7
25.1
41.5
M*
54
IIA
24
11
1.4
87.5
11.3
42.5
M
73
IIA
25
15.5
3.5
203.5
13.6
49.5
F*
76
IIA
26
13.3
1.5
70.7
33.1
43.2
M
65
IIB
32
1579
3.4
352.1
24.3
36.7
M*
74
IIB
27
10.9
3.4
0
28.0
35.3
F
74
IIB
40
43
3.2
54
25.8
38.9
F
68
IIB
27
302
2.1
82.8
40.8
36.4
M
61
IIB
30
10
1.4
134.7
27.3
46.2
M
63
IIB
15
1080
—
144.6
23.9
53.3
M*
73
IIB
50
13.9
2.1
23.2
1.8
43.1
F
62
IIB
25
11.5
1.1
111.7
28.4
43.1
Ave ± SD
CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protein, RBP4: plasma retinol binding protein 4. The stars indicate the patient who had a normal CA19-9 level and a low ApoA-IV. Ave: average. SD: standard deviation. AU: arbitrary unit.
(b) Serum tumor marker levels in healthy controls.
Gender
Age (years)
CA19-9 (u/mL)
CEA (ng/mL)
ApoA-IV (AU)
GC (AU)
RBP4 (AU)
M
71
33.9
2.2
157.4
29.5
47.7
M
55
0.1
4.7
243.8
35.0
48.5
M
55
6.4
1
223.0
35.3
54.3
M
55
0.1
3.5
237.1
33.0
48.1
M
60
7.7
0.8
237.1
23.9
44.1
M
60
37.4
7
214.0
39.6
48.8
M
61
7.6
4.8
277.0
16.8
49.7
F
77
7.1
1.1
294.5
24.2
43.7
M
61
7.8
1.3
80.6
33.4
55.3
F
61
6
3
210.1
45.8
56.3
F
65
2.9
2.1
65.7
61.7
53.3
M
66
5.1
0.7
156.7
33.8
44.7
F
62
11.7
1.7
122.9
33.0
50.9
F
64
8.4
1.2
222.9
38.7
50.3
F
71
24.4
2.6
184.7
30.5
56.3
Ave ± SD
CA19-9: carbohydrate antigen, CEA: carcinoembryonic antigen, ApoA-IV: apolipoprotein A-IV, GC: vitamin D-binding protien, RBP4: plasma retinol binding protein Ave: average. SD: standard deviation. AU: arbitrary unit.